Led · Series D · Sep 2024

CSA Medical develops the RejuvenAir System, a liquid nitrogen spray cryotherapy device intended to treat chronic bronchitis in COPD patients. The company says the technology targets overproduction of mucus and damaged cilia by destroying damaged cells without creating scar tissue, enabling regrowth of healthy airway cells. Led by CEO Wendelin Maners, CSA Medical is preparing a comprehensive commercialization strategy and plans a U.S. launch. The company intends to use the new funds to finance that U.S. launch despite an anticipated premarket approval (PMA) from the U.S. Food and Drug Administration. Board additions tied to the financing include Dr. Luc Marengere of TVM and Dr. Deng Mao of Yonjin Ventures. The company positions RejuvenAir as a therapeutic platform for an under-served patient population with chronic bronchitis. CSA Medical develops and manufactures proprietary interventional spray cryotherapy platforms—truFreeze and Rejuvenair—using liquid nitrogen spray delivered by a software‑driven device with specialty catheters to flash‑freeze and destroy unwanted tissue. The company manufactures and distributes the truFreeze system in the U.S., where it is being used in over 100 hospitals and universities to treat conditions such as Barrett’s esophagus, esophageal cancer, and airway obstructions. Its RejuvenAir Metered Cryospray system is designed to ablate mucus‑producing goblet cells while preserving the extracellular matrix and is currently under clinical investigation. Rejuvenair is not yet commercially available as it advances toward clinical and regulatory milestones. Led by Executive Chairman Vincent P. Owens, the company intends to expand commercial adoption of truFreeze in the GI market while progressing Rejuvenair through clinical development. CSA Medical develops the truFreeze spray cryotherapy system that uses super-cold liquid nitrogen delivered via catheter to ablate unwanted tissue inside the body. The company is based in Baltimore. In 2013 CSA raised $16 million in a Series C led by Ascension Ventures, which it planned to use to expand its R&D footprint in Lexington, Mass. CSA is currently pursuing a debt offering targeted at $3.9 million and has raised a little more than $2.9 million to date. The debt offering includes options and warrants and has attracted some 30 unnamed investors so far. Publicly listed backers on the company's website include Ascension, SV Life Sciences, Intersouth Partners, First Analysis, Rose Park Advisors and Blue Heron Capital. CSA Medical develops and manufactures a proprietary interventional spray cryotherapy platform comprised of a device and specialty catheters that deliver extremely cold (-196°C) liquid nitrogen to flash-freeze and destroy unwanted tissue inside the body. The truFreeze System has been used by physicians to ablate tissue in the esophagus and airway and is designed to destroy frozen cells while preserving underlying connective tissue to allow healthy cells to regenerate. The company completed a $16 million Series C financing to support growth and product development. Proceeds will be used to develop new applications, immediately double the sales force, and introduce new products in 2014. The Series C was led by Ascension Ventures and was oversubscribed with all existing investors participating. Tara Butler, MD of Ascension Ventures will join CSA Medical's board, indicating active investor engagement. CSA Medical develops and manufactures the Spray Cryotherapy System, a therapeutic interventional platform that delivers -196°C liquid nitrogen via a device and specialty catheters to freeze and destroy unwanted tissue inside the body. The system is currently used via endoscopic application to treat esophageal disease. Its product is being used at more than 80 top-ranked cancer centers and academic teaching hospitals across the United States. Proceeds from the recent financing will fund post-market clinical studies and ongoing development to support new indications and expanded utilization. Management intends to support the launch of a new platform and pursue new clinical applications, including therapeutic treatments for the airway. The company completed a $20.5 million Series B to support growth and expansion of its patented and currently marketed system.

Led · Series C · Apr 2024

Smart Reporting is a Munich-based medical reporting company focused on radiology and pathology that develops SmartReports, a fully voice-controlled and data-driven documentation solution. The software delivers high-quality, machine-readable data in real time and enables workflow automation for clinicians. Its multilingual structured-diagnostics platform is used by more than 16,000 physicians in over 90 countries and is developed by an interdisciplinary team of more than 80 doctors, data scientists, and software engineers. Smart Reporting distributes its software internationally via major healthcare IT partners including Siemens Healthineers, GE Healthcare and Canon. The company recently intensified a partnership with Solventum (formerly 3M Health Information Systems) to strengthen its North American presence. It plans to use new funding to expand international partnerships, accelerate product development, and grow its market presence in the US, Canada, Australia and New Zealand. Smart Reporting develops AI-supported, voice-controlled medical documentation and diagnostic software that collects, structures and processes clinical data across radiology, pathology and other clinical areas. Its technology produces fully evaluable, machine-readable results that the company says reduce time to diagnosis, improve diagnostic quality, automate manual processes and ease communication with referring physicians. The software aims to contribute to healthcare digitalization and to optimize patient care. Led by co-CEOs Wieland Sommer and Peter Vanovertveld, the company intends to use new financing to expand its technology position, enter new markets and further scale its software and data business. Financially, the company has secured a €15M venture debt loan to support these plans. No operating metrics were provided in the article. Smart Reporting offers multilingual, cloud-based software that enables structured medical reporting, initially launched for radiology and now used in pathology. The platform applies guideline-compliant criteria to generate high-quality, reproducible reports and can integrate with speech recognition, speech commands, and image-analysis/AI tools. Its software is used by more than 10,000 physicians in over 90 countries. The company has developed specialized templates such as a COVID-19 decision-tree for radiologists, which attracted over 2,000 registrations shortly after release. Smart Reporting plans to use recent funding to further develop its technology and to scale the solution into additional medical disciplines including surgery, oncology, and cardiology. The startup emphasizes improving data quality and enabling real-time analytics to support personalized care and efficiency in clinical workflows. Smart Reporting is a Munich, Germany–based IT-health startup that develops ImageREPORT, a software project combining intelligent image recognition for medical imaging with semiautomated structured reporting. The product couples a machine learning–based image analysis system with an intelligent structured-reporting engine that processes results and guides radiologists step-by-step through report creation. In practice, X-ray and CT images are analyzed automatically using deep learning–based computer-aided detection algorithms that can identify subtle anomalies. Image analysis outputs are then fed into the reporting software to streamline and standardize radiology reports. The company says it will use EU funding to continue advancing ImageREPORT and improve radiological care by linking image analysis and structured reporting. Project partners on ImageREPORT include Thirona and Radboud university medical center in Nijmegen.

Led · Series A · Feb 2024

Vektor Medical builds vMap, an AI-based, non-invasive arrhythmia analysis platform that uses a 12-lead ECG to localize arrhythmia sources and provide actionable insights to electrophysiologists. vMap is FDA-cleared and is being used by leading EPs in the U.S. to streamline ablation procedures and improve patient outcomes. The company plans to expand commercialization efforts, increase clinical support, and drive additional clinical studies to demonstrate clinical impact. Vektor is also pursuing reimbursement efforts to broaden access to the technology. The company is headquartered in San Diego. Its recent $16 million Series A will fund these commercialization and clinical initiatives.

Participated · Series A · Jan 2024

Myosotis offers a software-as-a-service solution for direct digital communication between employees, relatives, and third-party service providers in care homes. The app supports photos, videos, voice messages and video calls, consolidating most communication and administrative processes into a single digital application. Led by CEO Jasper Böckel, myo enables homes to inform relatives about hygiene measures, let families participate in residents' lives, and notify doctors, pharmacies or external laundry services. The company works with over 400 customers in DACH and the UK, including DRK, AWO, Johanniter and Agaplesion. Myosotis raised €8M in Series A funding and intends to use the proceeds to grow in the DACH region and the UK, expand marketing capacity, enhance service quality, and develop new modules. The financing will support continued roll-out of their technology to more users and additional solutions for healthcare providers and families.

Led · Series B · Mar 2021

Access Vascular manufactures intravenous catheters from a proprietary hydrophilic biomaterial called MIMIX™ that is engineered to mimic the body’s natural chemistry and evade the foreign body response. Its FDA-cleared products include HydroPICC®, HydroPICC® Dual, and HydroMID®, and the MIMIX material is patented. Preclinical and retrospective data presented by the company show a six-fold decrease in complications compared with standard polyurethane catheters, a four-log reduction in bacterial adhesion in an in vitro blood loop model, and a 96% reduction in thrombus accumulation in tested models. The company positions its technology as a way to lower the substantial costs and patient harms associated with vascular access complications. Access Vascular plans to use new funding to ramp production capacity for MIMIX-based devices, to pursue further research into lowering catheter infection rates, and to expand its product portfolio. Leadership frames the technology as poised to transform the standard of care for vascular access. Access Vascular has developed a proprietary hydrophilic, lubricious biomaterial and incorporated it into two commercial venous access devices: the HydroPICC Peripherally Inserted Central Catheter and the HydroMID Midline Catheter. In vitro (and referenced in vivo) studies reported an average 97% reduction in thrombus accumulation on its material versus standard polyurethane catheters. The company was founded in 2015 and is headquartered in Bedford, Mass. Current commercial products are on the market while the company pursues additional clinical and post-market data generation. Planned uses for new capital include generating post-market data on its two devices, expanding its device portfolio, and commercializing that expanded portfolio. The company targets reductions in infection, thrombosis and phlebitis through long-term thrombus-resistant biomaterials. Access Vascular, founded in 2015 by CEO James Biggins, develops intravenous catheters and ports from patented biomaterials that are biocompatible and intended to provide long-term infection protection. Its materials and devices are designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma. The company's first product, the FDA-cleared HydroPICCTM, began commercial use in early 2019. Future applications cited include midlines, dialysis catheters, ports, and other devices. The company intends to expand its portfolio of reduced-thrombosis intravenous devices through continued product development. It plans to use new funding to launch HydroPICC and to initiate its first post-market registry study. Access Vascular is a Bedford, MA–based medical device company developing venous access devices intended to eliminate thrombotic risk. Its lead product, the HydroPICC™, is a peripherally inserted central catheter that has shown in lab testing a reduction in platelet accumulation and therefore thrombosis risk. The company's pipeline includes midlines, a dialysis catheter and ports, all at various stages of development. Access Vascular plans to use the newly raised funds to support submission of a 510(k) application later this year for the HydroPICC. The company raised $3.7M in financing and is led by founder, president and CEO James Biggins. Backers include individual investors and AngelMD, an investment platform and marketplace connecting medical startups, physicians, investors and industry partners.